CLOUD

Tyler O'Neal, Staff Editor CLOUD

Bina Technologies Expands Scientific Advisory Board and Commercial Team

With new additions, Bina Technologies poised to impact the clinical research market with best-in-class analytical workflows

Bina Technologies has announced the expansion of their advisory board and commercial team. This announcement marks the latest in the company’s initiatives to significantly improve genomics data analysis workflows used in clinical research. Bina has expanded its Scientific Advisory Board, adding four luminaries with deep experience in clinical genomics research. The company has also brought on two commercial team leaders, tapping into their combined 40+ years of experience driving revolutionary technologies into the genomics market.

In addition to existing SAB members Dr. Wing Wong, a professor of Statistics and of Health Research and Policy at Stanford University; Dr. Garry Nolan, Professor of Microbiology and Immunology at the Stanford School of Medicine and co-founder of several biotechnology companies including Rigel and Nodality; and Dr. Wawrzynek, Professor of Engineering and Computer Sciences at UC Berkeley, Bina has added clinical genomicists Dr. Robert Green, Dr. Shashikant Kulkarni, Dr. Rong Chen, and bioinformaticist Dr. Mark Gerstein. The SAB now includes an impressive team of experts across the disciplines of clinical research, genomics, computer science and engineering, and bioinformatics.

“The extensive experience of our new SAB members, each having distinguished themselves in clinical research, will be one of the driving factors in achieving Bina’s goal of revolutionizing clinical care by providing researchers with the tools to quickly and easily analyze large genomic data, ultimately helping with patient diagnosis, prognosis and therapeutic selection,” said Narges Bani Asadi, CEO of Bina Technologies. “These experts will help assure that Bina’s analytical tools will enable the clinical research community to revolutionize medical care.”

The expanded SAB will offer expert guidance in providing tools that address the fields’ significant challenges around handling complex next-generation sequencing data sets. With the expanded SAB and new commercial leaders, Bina will focus on delivering powerful, accurate and easy-to-use analytical tools that enable the clinical research community.

“The clinical and research communities working in genomics need tools that make it faster and easier to manage the massive amounts of genomic data that we deal with on a daily basis,” said Dr. Robert C. Green. “I look forward to working with Bina Technologies to help them develop new products that clinicians and researchers can rely upon for more accurate and complete data analysis in genomics.”

To learn more about Bina’s Scientific Advisory Board, please see: http://www.binatechnologies.com/company.

In addition to the SAB, Bina is also growing its executive team with two new hires. Janet Lankard has been hired as VP of Sales, and Gianfranco de Feo, Ph.D. has joined Bina as VP of Marketing.

“Together, Gianfranco and Janet bring 40 years of deep industry knowledge to Bina. Each of them have been fundamental in establishing groundbreaking new technologies, such as qPCR and microarrays, in the pharmaceutical, basic and clinical research communities,” said Narges Bani Asadi, CEO of Bina Technologies. “With their help, we’re well on our way to making good on our mission to bring personalized medicine to the clinical market.”

Bina Technologies will be demonstrating their latest products at the Personalized Medicine World Conference from January 27-28. Attendees are invited to visit the Bina team in Booth #22 in the main exhibition area of the Computer History Museum in Mountain View, California.

To learn more about Bina Technologies, please visit: http://binatechnologies.com.

TRENDING